Chronic autoimmune-mediated inflammation: a senescent immune response to injury.

Abstract:

:The increasing prevalence of chronic autoimmune-mediated inflammatory diseases (AIMIDs) in ageing western societies is a major challenge for the drug development industry. The current high medical need for more-effective treatments is at least in part caused by our limited understanding of the mechanisms that drive chronic inflammation. Here, we postulate a role for immunosenescence in the progression of acute to chronic inflammation via a dysregulated response to primary injury at the level of the damaged target organ. A corollary to this notion is that treatment of acute versus chronic phases of disease might require differential targeting strategies.

journal_name

Drug Discov Today

journal_title

Drug discovery today

authors

't Hart BA,Chalan P,Koopman G,Boots AM

doi

10.1016/j.drudis.2012.11.010

subject

Has Abstract

pub_date

2013-04-01 00:00:00

pages

372-9

issue

7-8

eissn

1359-6446

issn

1878-5832

pii

S1359-6446(12)00396-0

journal_volume

18

pub_type

杂志文章,评审
  • Stapled peptide induces cancer cell death.

    abstract::Hydrocarbon stapling could enable peptides from the key domains of natural proteins to be used therapeutically. Using the technique on a peptide involved in apoptosis, researchers have succeeded in destroying cancer cells in a mouse model of leukaemia. ...

    journal_title:Drug discovery today

    pub_type: 新闻

    doi:10.1016/S1359-6446(04)03268-4

    authors: Whelan J

    更新日期:2004-11-01 00:00:00

  • Improvement of preclinical animal models for autoimmune-mediated disorders via reverse translation of failed therapies.

    abstract::The poor translational validity of autoimmune-mediated inflammatory disease (AIMID) models in inbred and specific pathogen-free (SPF) rodents underlies the high attrition of new treatments for the corresponding human disease. Experimental autoimmune encephalomyelitis (EAE) is a frequently used preclinical AIMID model....

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2014.03.023

    authors: 't Hart BA,Jagessar SA,Kap YS,Haanstra KG,Philippens IH,Serguera C,Langermans J,Vierboom M

    更新日期:2014-09-01 00:00:00

  • Clinical implications of leukocyte infiltration at the choroid plexus in (neuro)inflammatory disorders.

    abstract::The choroid plexus (CP) is a highly vascularized organ located in the brain ventricles and contains a single epithelial cell layer forming the blood-cerebrospinal fluid barrier (BCSFB). This barrier is crucial for immune surveillance in health and is an underestimated gate for entry of immune cells during numerous inf...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2015.05.003

    authors: Demeestere D,Libert C,Vandenbroucke RE

    更新日期:2015-08-01 00:00:00

  • Peripheral modulation of the endocannabinoid system in metabolic disease.

    abstract::Dysfunction of the endocannabinoid system (ECS) has been identified in metabolic disease. Cannabinoid receptor 1 (CB1) is abundantly expressed in the brain but also expressed in the periphery. Cannabinoid receptor 2 (CB2) is more abundant in the periphery, including the immune cells. In obesity, global antagonism of o...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2018.01.029

    authors: Shrestha N,Cuffe JSM,Hutchinson DS,Headrick JP,Perkins AV,McAinch AJ,Hryciw DH

    更新日期:2018-03-01 00:00:00

  • Accelerating biomedical innovation: a case study of the SPARK program at Stanford University, School of Medicine.

    abstract::Translating academic medical research into new therapies is an important challenge for the biopharmaceutical industry and investment communities, which have historically favored later-stage assets with lower risk and clearer commercial value. The Stanford SPARK program is an innovative model for addressing this challe...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2017.03.015

    authors: Kim ES,Omura PMC,Lo AW

    更新日期:2017-07-01 00:00:00

  • Molecular diversity and its analysis.

    abstract::We have recently developed a novel strategy for the rational design of compounds. This 'in silico screening' approach is based on the design and screening of virtual combinatorial libraries. Screening is performed using defined rules derived from a comprehensive description of active and inactive molecules in a releva...

    journal_title:Drug discovery today

    pub_type: 杂志文章

    doi:10.1016/s1359-6446(99)01334-3

    authors: Gorse D,Rees A,Kaczorek M,Lahana R

    更新日期:1999-06-01 00:00:00

  • p53 family interactions and yeast: together in anticancer therapy.

    abstract::The p53 family proteins are among the most appealing targets for cancer therapy. A deeper understanding of the complex interplay that these proteins establish with murine double minute (MDM)2, MDMX, and mutant p53 could reveal new exciting therapeutic opportunities in cancer treatment. Here, we summarize the most rele...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2016.02.007

    authors: Gomes S,Leão M,Raimundo L,Ramos H,Soares J,Saraiva L

    更新日期:2016-04-01 00:00:00

  • EU marketing authorization review of orphan and non-orphan drugs does not differ.

    abstract::Marketing authorization application dossiers of 17 orphan drugs (ODs) and 51 non-ODs evaluated by the European Medicines Agency (EMA) in the period 2009-2010 were compared. We aimed to identify whether any differences existed between ODs and non-ODs in number and type of deficits brought forward during the EMA review,...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2013.06.012

    authors: Putzeist M,Mantel-Teeuwisse AK,Llinares J,Gispen-De Wied CC,Hoes AW,Leufkens HG

    更新日期:2013-10-01 00:00:00

  • Snapshot PK: a rapid rodent in vivo preclinical screening approach.

    abstract::Described in this article are strategies implemented to increase the throughput of in vivo rodent pharmacokinetic (PK) studies using the snapshot PK study design and automated methods for compound submission, sample processing, data analysis and reporting. Applying snapshot PK studies to categorize the oral exposure o...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2007.10.014

    authors: Liu B,Chang J,Gordon WP,Isbell J,Zhou Y,Tuntland T

    更新日期:2008-04-01 00:00:00

  • E-drug delivery: a futuristic approach.

    abstract::Drug delivery systems are undergoing technology changes to enhance patient comfort and compliance. Electronic drug delivery (E-drug delivery) systems are being developed to regulate drug dose delivery by easy monitoring of doses, especially in chronic and age-related diseases. E-drug delivery can monitor the correct d...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2019.02.005

    authors: Yadav KS,Kapse-Mistry S,Peters GJ,Mayur YC

    更新日期:2019-04-01 00:00:00

  • Molecule-pharmacophore superpositioning and pattern matching in computational drug design.

    abstract::Three-dimensional (3D) pharmacophore modeling is a technique for describing the interaction of a small molecule ligand with a macromolecular target. Since chemical features in a pharmacophore model are well known and highly transparent for medicinal chemists, these models are intuitively understandable and have been i...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2007.09.007

    authors: Wolber G,Seidel T,Bendix F,Langer T

    更新日期:2008-01-01 00:00:00

  • Monitor: molecules and profiles.

    abstract::Monitor provides an insight into the latest developments in drug discovery through brief synopses of recent presentations and publications together with expert commentaries on the latest technologies. There are two sections: Molecules summarizes the chemistry and the pharmacological significance and biological relevan...

    journal_title:Drug discovery today

    pub_type: 杂志文章

    doi:10.1016/s1359-6446(01)01877-3

    authors: Barlocco D,Langston S,Tranter D

    更新日期:2001-08-01 00:00:00

  • Top 100 bestselling drugs represent an arena struggling for new FDA approvals: drug age as an efficiency indicator.

    abstract::We analyzed a list of the top 100 bestselling drugs as a struggling market for new FDA approvals. Using the time from drug approval by the FDA as a measure of drug age, our analysis showed that the top 100 bestselling drugs are getting older. This reflects the stalled launch of new drugs into the market during recent ...

    journal_title:Drug discovery today

    pub_type: 杂志文章

    doi:10.1016/j.drudis.2015.06.015

    authors: Polanski J,Bogocz J,Tkocz A

    更新日期:2015-11-01 00:00:00

  • Immunoinformatics: current trends and future directions.

    abstract::Immunoinformatics has recently emerged as a critical field for accelerating immunology research. Although still an evolving process, computational models now play instrumental roles, not only in directing the selection of key experiments, but also in the formulation of new testable hypotheses through detailed analysis...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2009.04.001

    authors: Tong JC,Ren EC

    更新日期:2009-07-01 00:00:00

  • Fsp3: A new parameter for drug-likeness.

    abstract::The drug-likeness of a compound is a key factor during the initial phases of drug discovery. It can be defined as the similarity between compounds and drugs. Here, we collate research related to the fraction of sp3 carbon atoms (Fsp3), including related high-throughput screening (HTS) cases, structural modifications b...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2020.07.017

    authors: Wei W,Cherukupalli S,Jing L,Liu X,Zhan P

    更新日期:2020-07-24 00:00:00

  • Can hi-jacking hypoxia inhibit extracellular vesicles in cancer?

    abstract::Increasing evidence indicates that extracellular vesicles (EVs) are key players in undesirable cell-cell communication in cancer. However, the release of EVs is not unique to cancer cells; normal cells release EVs to perform physiological roles. Thus, selective inhibition of EV release from cancer cells is desirable. ...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2018.03.006

    authors: Lowry MC,O'Driscoll L

    更新日期:2018-06-01 00:00:00

  • Histone acetyl transferases as emerging drug targets.

    abstract::Post-translational modifications, such as acetylation or phosphorylation, play a crucial role in the regulation of gene transcription in eukaryotes. Different subtypes of histone acetyl transferases (HATs) catalyze the acetylation of histones on specific lysine residues. A potential role of HATs in the pathology of ca...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2009.06.008

    authors: Dekker FJ,Haisma HJ

    更新日期:2009-10-01 00:00:00

  • What is precise pathophysiology in development of hypertension in pregnancy? Precision medicine requires precise physiology and pathophysiology.

    abstract::It is widely accepted that placental ischemia is central in the evolution of hypertension in pregnancy. Many studies and reviews have targeted placental ischemia to explain mechanisms for initiating pregnancy hypertension. The placenta is rich in blood vessels, which are the basis for developing placental ischemia. Ho...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2017.10.021

    authors: Gao Q,Tang J,Li N,Liu B,Zhang M,Sun M,Xu Z

    更新日期:2018-02-01 00:00:00

  • Physicochemical properties affecting the fate of nanoparticles in pulmonary drug delivery.

    abstract::The inhaled delivery of nanomedicines has attracted much attention in the treatment of lung diseases or systemic diseases. However, there is a lack of understanding about their fate upon lung delivery. Thus, the objective of this review is to summarize physicochemical properties affecting the fate of nanoparticles aft...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2019.09.023

    authors: Liu Q,Guan J,Qin L,Zhang X,Mao S

    更新日期:2020-01-01 00:00:00

  • Diagnostic challenges for multiplexed protein microarrays.

    abstract::Multiplexed protein analysis using planar microarrays or microbeads is growing in popularity for simultaneous assays of antibodies, cytokines, allergens, drugs and hormones. However, this new assay format presents several new operational issues for the clinical laboratory, such as the quality control of protein-microa...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2006.09.010

    authors: Master SR,Bierl C,Kricka LJ

    更新日期:2006-11-01 00:00:00

  • Catabolic mediators as targets for cancer cachexia.

    abstract::The cachexia syndrome, characterized by a marked weight loss, anorexia, asthenia and anaemia, is invariably associated with the growth of a tumour and leads to a malnutrition status caused by the induction of anorexia or decreased food intake. In addition, the competition for nutrients between the tumour and the host ...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/s1359-6446(03)02826-5

    authors: Argilés JM,Moore-Carrasco R,Busquets S,López-Soriano FJ

    更新日期:2003-09-15 00:00:00

  • Docking optimization, variance and promiscuity for large-scale drug-like chemical space using high performance computing architectures.

    abstract::There is a continuing need to hasten and improve protein-ligand docking to facilitate the next generation of drug discovery. As the drug-like chemical space reaches into the billions of molecules, increasingly powerful computer systems are required to probe, as well as tackle, the software engineering challenges neede...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2016.06.023

    authors: Trager RE,Giblock P,Soltani S,Upadhyay AA,Rekapalli B,Peterson YK

    更新日期:2016-10-01 00:00:00

  • Recent computational advances in the identification of allosteric sites in proteins.

    abstract::Allosteric modulators have the potential to fine-tune protein functional activity. Therefore, the targeting of allosteric sites, as a strategy in drug design, is gaining increasing attention. Currently, it is not trivial to find and characterize new allosteric sites by experimental approaches. Alternatively, computati...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2014.07.012

    authors: Lu S,Huang W,Zhang J

    更新日期:2014-10-01 00:00:00

  • Optimizing the use of open-source software applications in drug discovery.

    abstract::Drug discovery is a time consuming and costly process. Recently, a trend towards the use of in silico computational chemistry and molecular modeling for computer-aided drug design has gained significant momentum. This review investigates the application of free and/or open-source software in the drug discovery process...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/S1359-6446(05)03692-5

    authors: Geldenhuys WJ,Gaasch KE,Watson M,Allen DD,Van der Schyf CJ

    更新日期:2006-02-01 00:00:00

  • Building relationships between academia and the pharmaceutical industry.

    abstract::'The climate is perfect for a proactive search for partners between industry and academia.' ...

    journal_title:Drug discovery today

    pub_type: 杂志文章

    doi:10.1016/s1359-6446(00)01543-9

    authors: Dean P

    更新日期:2000-09-01 00:00:00

  • Timely synthetic support for medicinal chemists.

    abstract::In recent years, there have been significant developments made in the way new drugs are being discovered and developed. Such changes are driven by new technologies that have expanded the opportunities to prepare and screen large libraries of compounds in a rapid time frame by the use of high-throughput synthesis and s...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/S1359-6446(04)03298-2

    authors: Potoski J

    更新日期:2005-01-15 00:00:00

  • Cancer therapy via modulation of micro RNA levels: a promising future.

    abstract::Micro RNAs (miRNAs) are a class of naturally occurring ∼ 22 nt long non-coding small RNA molecules that regulate the expression of a wide range of genes involved in development, growth, proliferation and apoptosis. miRNAs are evolutionarily conserved from plants to animals, and they regulate and fine-tune a diverse ar...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2010.07.003

    authors: Kota SK,Balasubramanian S

    更新日期:2010-09-01 00:00:00

  • Miniaturized HTS technologies - uHTS.

    abstract::The transition from slow, manual, low-throughput screening to industrialized robotic ultra-high throughput screening (uHTS) in the past few years has made it possible to screen hundreds of thousands of chemical entities against a biological target in a short time-frame. The need to minimize the cost of screening has b...

    journal_title:Drug discovery today

    pub_type: 杂志文章

    doi:10.1016/s1359-6446(01)01807-4

    authors: Wölcke J,Ullmann D

    更新日期:2001-06-01 00:00:00

  • Knowledge-based chemoinformatic approaches to drug discovery.

    abstract::The modern drug discovery process is steadily becoming more information driven. Structural, physicochemical and ADME-Tox property profiles of reference (successful) ligands, along with structural information of their target proteins, have been extremely useful for early-stage drug discovery. Recently, databases of kno...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2006.10.012

    authors: Ghose AK,Herbertz T,Salvino JM,Mallamo JP

    更新日期:2006-12-01 00:00:00

  • Analysis of clinical trials of new drugs in China as of 2019.

    abstract::The research and development (R&D) of new drugs indicates scientific progress and economic development. However, little is known regarding ongoing or recent clinical trials in China. We analyzed data from clinical trials published before December 31, 2019, and found that the annual registration numbers are increasing ...

    journal_title:Drug discovery today

    pub_type: 杂志文章

    doi:10.1016/j.drudis.2020.09.030

    authors: Lin L,Chen Y,Yan L,Liu Y,Ni J,Yang H,Li H

    更新日期:2020-12-01 00:00:00